Skip Navigation


Carcinogenesis Advance Access originally published online on May 5, 2005
Carcinogenesis 2005 26(9):1627-1633; doi:10.1093/carcin/bgi114
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
26/9/1627    most recent
bgi114v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Abdalla, S. I.
Right arrow Articles by Fitzgerald, R. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Abdalla, S. I.
Right arrow Articles by Fitzgerald, R. C.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Carcinogenesis vol.26 no.9 © Oxford University Press 2005; all rights reserved.

Effect of inflammation on cyclooxygenase (COX)-2 expression in benign and malignant oesophageal cells

Salem I. Abdalla 1, 2, Ian R. Sanderson 2 and Rebecca C. Fitzgerald 1, *

1 Cancer Cell Unit, Hutchison/MRC Research Centre, Hills Road, Cambridge CB2 2XZ, UK and 2 Institute of Cell and Molecular Science, Adult and Paediatric Gastroenterology Department, Barts and the London School of Medicine and Dentistry, London, UK

* To whom correspondence should be addressed. Tel: 0044 1223 763287; Fax: 0044 1223 763296; Email: rcf{at}hutchison-mrc.cam.ac.uk

Chronic inflammation has been linked to carcinogenesis in various tissue sites. Barrett's oesophageal epithelium (BE) is a premalignant condition in which cyclooxygenase-2 (COX-2) levels are increased. However, it is not clear whether the primary stimulus for the high COX-2 levels is related to inflammation or malignancy. The effect of exogenous cytokines (IL-1ß, IL-10 and IL-13) on COX-2 expression was assessed by western blotting in three BE cancer cell lines (SEG-1, BIC-1 and OE33) and a squamous cancer cell line (OE21). Primary tissue was assessed from 17 patients with long BE segments, 13 oesophagitis, 30 oesophageal adenocarcinoma (EAC), and 40 normal oesophageal (NE) and duodenal (DU) controls. COX-2 protein expression was determined by western blotting and its tissue localization was examined using immunohistochemistry. COX-2 protein and the neutrophil marker myeloperoxidase (MPO) were quantified along BE segments. The leukocyte marker CD45 was used to identify any correlation between COX-2 expression and leukocyte cell distribution in EAC. IL-1ß induced COX-2 expression in SEG-1 cells (P < 0.05), whereas IL-10 and IL-13 had no effect. COX-2 protein levels were found to be increased in distal BE > proximal BE > oesophagitis > NE (P < 0.001). COX-2 expression in EAC was heterogeneous and the overall levels were not significantly increased. The increased COX-2 expression in distal BE was not associated with inflammation (MPO expression). In addition, there was no correlation between COX-2 and CD45 in AC. COX-2 protein expression in the oesophagus appears to be independent of the degree of inflammation.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Therapeutic Advances in GastroenterologyHome page
J. A. Abrams
Review: Chemoprevention of esophageal adenocarcinoma
Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 7 - 18.
[Abstract] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
H. R. Ferguson, C. P. Wild, L. A. Anderson, S. J. Murphy, B. T. Johnston, L. J. Murray, R.G. P. Watson, J. McGuigan, J. V. Reynolds, and L. J. Hardie
Cyclooxygenase-2 and Inducible Nitric Oxide Synthase Gene Polymorphisms and Risk of Reflux Esophagitis, Barrett's Esophagus, and Esophageal Adenocarcinoma
Cancer Epidemiol. Biomarkers Prev., March 1, 2008; 17(3): 727 - 731.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
L. Duan, A. H. Wu, J. Sullivan-Halley, and L. Bernstein
Nonsteroidal Anti-inflammatory Drugs and Risk of Esophageal and Gastric Adenocarcinomas in Los Angeles County
Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 126 - 134.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
S. R. Pine, L. E. Mechanic, S. Ambs, E. D. Bowman, S. J. Chanock, C. Loffredo, P. G. Shields, and C. C. Harris
Lung Cancer Survival and Functional Polymorphisms in MBL2, an Innate-Immunity Gene
J Natl Cancer Inst, September 19, 2007; 99(18): 1401 - 1409.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
O. Ogunwobi, G. Mutungi, and I. L. P. Beales
Leptin Stimulates Proliferation and Inhibits Apoptosis in Barrett's Esophageal Adenocarcinoma Cells by Cyclooxygenase-2-Dependent, Prostaglandin-E2-Mediated Transactivation of the Epidermal Growth Factor Receptor and c-Jun NH2-Terminal Kinase Activation
Endocrinology, September 1, 2006; 147(9): 4505 - 4516.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. A. Anderson, B. T. Johnston, R.G. P. Watson, S. J. Murphy, H. R. Ferguson, H. Comber, J. McGuigan, J. V. Reynolds, and L. J. Murray
Nonsteroidal Anti-inflammatory Drugs and the Esophageal Inflammation-Metaplasia-Adenocarcinoma Sequence.
Cancer Res., May 1, 2006; 66(9): 4975 - 4982.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
H. Lu, W. Ouyang, and C. Huang
Inflammation, a Key Event in Cancer Development
Mol. Cancer Res., April 1, 2006; 4(4): 221 - 233.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.